Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Abstract: Disclosed herein is a method of controlling power of a base station in a spectrum sharing environment, which includes setting, by a control device, predetermined initial power information for a plurality of base stations located in a service area in a time slot t; calculating, by the control device, a coverage radius for each of the base stations on the basis of the initial power information; calculating, by the control device, gradients of a coverage area and an interference area for each of the base stations on the basis of the coverage radius for each of the base stations; and updating, by the control device, power information for each of the base stations in a time slot t+1 on the basis of the gradients of each of the base stations.

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Abstract: A coil component includes a nonmagnetic body having a cured product of a polymer resin, an insulating substrate embedded in the body and having a thickness of 30 ?m or less, a coil portion including first and second coil patterns respectively disposed on first and second opposing surfaces of the insulating substrate, and first and second external electrodes disposed on a surface of the body to be connected to each of the first and second coil patterns exposed to the surface of the body.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: The present invention relates to a pitching training aid for shadow pitching training, the pitching training aid comprising: a receiving body which includes an inner receiving space and has openings at both sides thereof, and replicates a baseball in a state where a user encompasses and holds the receiving body with his/her hand or wears the receiving body on his/her fingers through the receiving space; a locking holder which is detachably inserted and fixed in the receiving space through the opening of the receiving body, and provides a locking region where locking through-holes are formed in the longitudinal direction, so as to allow at least one finger to be fitted and locked into the locking holder in the longitudinal direction, the locking holes extending in a curved shape having a predetermined curvature; and an elongated body which has a rod shape extending a predetermined length from one side of the receiving body, and provides load and vibration while being elastically deformed and restored by rotati

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: The present disclosure provides a radar apparatus capable of suppressing a radar-to-radar in-band interference caused by a signal derived from another radar apparatus in a radar system in which a plurality of radar apparatuses share frequency resource to increase a frequency utilization efficiency. The radar apparatus includes: a receiver configured to acquire a received signal; a plurality of matched filters arranged in parallel to filter the receive signal, each corresponding to respective one of the plurality of radar apparatus to use a transmit signal of a corresponding radar apparatus as a reference signal; and a signal reconstructor configured to select a matched filter most adequate for an interference suppression based on outputs of the plurality of matched filters, subtract the reference signal of a selected matched filter at least partially from the receive signal, and reconstruct a desired echo signal to be used to determine a target.

Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: Disclosed is a method and apparatus for generating a radar signal, in which performance of radar detection is ensured while increasing a spectrum efficiency in a radar network. The method comprises generating a set of frequency-modulation waveforms, generating an orthogonal code set, generating a set of coded frequency-modulation waveforms through element operation between the set of frequency-modulation waveforms and the orthogonal code set, calculating an objective function for the set of frequency-modulation waveforms with regard to a different set of coded frequency-modulation waveforms and previous sets of coded frequency-modulation waveforms, and selecting a current polyphase code set as an optimized polyphase code set when a result of current calculation is better or smaller than a result of previous iteration, and performing phase perturbation by replacing an element randomly selected in the current polyphase code set selected as the optimized polyphase code set with another admissible-phase element.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: A virtual space management unit 60 generates a virtual space information and manages the virtual space information. An icon position acquisition unit 61 acquires icon position information of each of the users U. A transmission-side voice acquisition unit 62 acquires a transmission-side voice information. A distance calculation unit 63 calculates a distance between each of the icons based on a position within the virtual space of the icons corresponding to each of the users U. A correction factor determination unit 64 determines a correction factor of an output information based on the distance between the icons calculated by the distance calculation unit 63. A reception-side voice transmission control unit 65 transmits the acquired transmission-side voice information and the determined correction factor to each of the second user terminals 3.

Abstract: A coil component includes a nonmagnetic body having a cured product of a polymer resin, an insulating substrate embedded in the body and having a thickness of 30 ?m or less, a coil portion including first and second coil patterns respectively disposed on first and second opposing surfaces of the insulating substrate, and first and second external electrodes disposed on a surface of the body to be connected to each of the first and second coil patterns exposed to the surface of the body.

Abstract: A light emitting display device and driving method are disclosed. A light emitting display device includes a display panel including RGBW sub-pixels; a driver configured to drive the display panel; and a timing controller configured to control the driver, wherein W peak luminance derived by the W sub-pixels is higher than a sum of RGB peak luminances derived by the RGB sub-pixels when the display panel displays an image.

Abstract: A all-solid-state battery includes a first battery cell in which a negative electrode current collector including a negative electrode lead portion, a first negative electrode layer, a first solid electrolyte layer and a first positive electrode layer are sequentially stacked, a second battery cell in which a second positive electrode layer, a second solid electrolyte layer and a second negative electrode layer are sequentially stacked, a third battery cell in which a third negative electrode layer, a third solid electrolyte layer, a third positive electrode layer, and a positive electrode current collector including a positive electrode lead portion are sequentially stacked, a first connection electrode connected to the first positive electrode layer and the second negative electrode layer, and a second connection electrode connected to the second positive electrode layer and the third negative electrode layer. The first to third battery cells are connected in series.

Abstract: An all-solid-state battery includes: a columnar battery cell, having a central axis extending in a first direction, in which a positive electrode active material, a positive electrode support, a solid electrolyte layer, a negative active material, and a negative electrode support are sequentially stacked from a center of the battery cell; a plurality of connection members disposed on both surfaces of the battery cell in a third direction; a negative electrode terminal connected to the connection members; and a positive electrode terminal connected to the connection members. The all-solid-state battery includes a groove portion disposed in the third direction of the battery cell and disposed in the first direction, and includes at least two battery cells.

Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.